2 completed, 1 active not recruiting, 1 not yet recruiting, 1 withdrawn. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified: new trials by email Literature Review of Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified trials Research Report on Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma Brentuximab Vedotin, Pembrolizumab - Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Withdrawn | Northwestern University | 2020-03-01 | 2023-10-10 | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 22 | 2012-10-29 | 2018-09-19 |
Lymphoma, T-Cell (5) · Enteropathy-Associated T-Cell Lymphoma (4) · Lymphoma, Large-Cell, Anaplastic (4) · Immunoblastic Lymphadenopathy (3) · Mycosis Fungoides (3) · Subcutaneous panniculitis-like T-cell lymphoma (3) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphadenopathy (3) · Lymphoma, T-Cell, Cutaneous (3)
10-propargyl-10-deazaaminopterin (2) · pembrolizumab (2) · AFM13 (1) · Azacitidine (1) · Brentuximab Vedotin (1) · Carboplatin (1) · Cyclophosphamide (1) · Depsipeptides (1) · Etoposide (1) · Fluorodeoxyglucose F18 (1) · Ifosfamide (1) · Lactones (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · belinostat (1)
City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · Northwestern University (1)
United States (5)
Alex F Herrera (1) · Christina Poh (1) · Jonathan Moreira, MD (1) · Michelle Fanale (1) · Yago L Nieto (1)
P30CA016672 (1), P30CA033572 (1), P30CA060553 (1)